Saturday 17 October 2026
Export RVLP’s income statement to Excel — free account
RVL Pharmaceuticals PLC
RVLP Healthcare Biotechnology
RVL Pharmaceuticals PLC’s revenue for fiscal 2022 (year ended December 2022) was $49.7 million.
Follow RVLP
| Older periods | Sep '22 | Dec '22 | Mar '23 | Jun '23 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 3 | 2 | 3 |
| (86.13%) | (80.88%) | (103.18%) | (182.44%) | ||
| (40.09%) | (37.84%) | (44.23%) | (64.94%) | ||
ROIC |
(55.09%) | (58.06%) | (61.84%) | (80.54%) | |
Return on Tangible Assets |
(105.97%) | (134.17%) | (231.19%) | 174.15% | |
Average Days of Receivables |
27.99 | 22.25 | 18.48 | 19.10 | |
Free Cash Flow per Share |
(0.49) | (0.43) | (0.33) | (0.48) | |
Free Cash Flow |
(45.64) | (38.56) | (32.34) | (47.41) | |
Capital Expenditures |
0.13 | (0.75) | (1.99) | (3.00) | |
| Other line items | |||||
Cash ROIC |
(24.70%) | (25.27%) | (24.91%) | (50.85%) | |
Accounts Receivable Turnover |
11.45 | 19.26 | 3.82 | 19.61 | |
Accounts Payable Turnover |
1.39 | 3.06 | 2.61 | 2.34 | |
Inventory Turnover |
11.04 | 11.66 | 18.29 | 9.90 | |
Average Days of Payables |
320.35 | 92.91 | 99.88 | 98.98 | |
Days of Inventory on Hand |
28.41 | 30.26 | 8.09 | 53.05 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.87% | 7.98% | 10.05% | 8.40% | |
Selling, General and Administrative Expense of Revenue |
205.90% | 164.88% | 200.34% | 184.35% | |
Share Based Compensation of Revenue |
9.77% | 8.19% | 9.05% | 6.45% | |
Interest Coverage |
(6.56) | (9.48) | (14.85) | (59.68) | |
Operating CF/Net income |
0.86 | 0.73 | 0.54 | 0.65 | |
Depreciation/Fixed assets |
2.94 | 13.13 | 6.35 | 8.91 | |
Capex/Depreciation |
0.07 | (0.04) | (0.13) | (0.10) | |
Revenue per Share |
0.46 | 0.55 | 0.37 | 0.37 | |
Operating CF per Share |
(0.49) | (0.42) | (0.31) | (0.45) | |
Capex per Share |
0.00 | (0.01) | (0.02) | (0.03) | |
Capex to Sales |
0.00 | 0.02 | 0.05 | 0.08 |
Columns are period end dates